Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
PDF vom PMID33103530  :  Publisher

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands #MMPMID33103530
  • Karami Z; Knoop BT; Dofferhoff ASM; Blaauw MJT; Janssen NA; van Apeldoorn M; Kerckhoffs APM; van de Maat JS; Hoogerwerf JJ; Ten Oever J
  • Infect Dis (Lond) 2021[Feb]; 53 (2): 102-110 PMID33103530show ga
  • BACKGROUND: Knowledge on bacterial co-infections in COVID-19 is crucial to use antibiotics appropriately. Therefore, we aimed to determine the incidence of bacterial co-infections, antibiotic use and application of antimicrobial stewardship principles in hospitalized patients with COVID-19. METHODS: We performed a retrospective observational study in four hospitals (1 university, 2 non-university teaching, 1 non-teaching hospital) in the Netherlands from March to May 2020 including consecutive patients with PCR-confirmed COVID-19. Data on first microbiological investigations obtained at the discretion of the physician and antibiotic use in the first week of hospital admission were collected. RESULTS: Twelve (1.2%) of the 925 patients included had a documented bacterial co-infection (75.0% pneumonia) within the first week. Microbiological testing was performed in 749 (81%) patients: sputum cultures in 105 (11.4%), blood cultures in 711 (76.9%), pneumococcal urinary antigen testing in 202 (21.8%), and Legionella urinary antigen testing in 199 (21.5%) patients, with clear variation between hospitals. On presentation 556 (60.1%; range 33.3-73.4%) patients received antibiotics for a median duration of 2 days (IQR 1-4). Intravenous to oral switch was performed in 41 of 413 (9.9%) patients who received intravenous treatment >48 h. Mean adherence to the local guideline on empiric antibiotic therapy on day 1 was on average 60.3% (range 45.3%-74.7%). CONCLUSIONS: On presentation to the hospital bacterial co-infections are rare, while empiric antibiotic use is abundant. This implies that in patients with COVID-19 empiric antibiotic should be withheld. This has the potential to dramatically reduce the current overuse of antibiotics in the COVID-19 pandemic.
  • |*Pandemics[MESH]
  • |Aged[MESH]
  • |Anti-Bacterial Agents/*administration & dosage[MESH]
  • |Antimicrobial Stewardship[MESH]
  • |Bacterial Infections/*drug therapy/*epidemiology/microbiology[MESH]
  • |Blood Culture[MESH]
  • |COVID-19/*epidemiology/virology[MESH]
  • |Coinfection[MESH]
  • |Drug Administration Routes[MESH]
  • |Drug Administration Schedule[MESH]
  • |Female[MESH]
  • |Guideline Adherence/statistics & numerical data[MESH]
  • |Hospitalization[MESH]
  • |Humans[MESH]
  • |Incidence[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |Netherlands/epidemiology[MESH]
  • |Prescription Drug Overuse/prevention & control/*statistics & numerical data[MESH]
  • |Retrospective Studies[MESH]
  • |SARS-CoV-2/pathogenicity[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    102 2.53 2021